|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to validate the use of PCR-RFLP techniques for the evaluation of p53 codon 72 and CYP1A1 gene polymorphisms in relation with ovarian cancer in a Romanian population and to evaluate gene-environment interaction in this context.
|
22395499 |
2012 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
It was speculated that p53 function was lost by TP53 germline mutation with the loss of a wild type allele induced by the chemotherapy against ovarian cancer, leading to the development of MDS.
|
15942101 |
2005 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Further analysis of TP53 gene mutations in ovarian cancer by geography could provide greater insights.
|
16907706 |
2006 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism?
|
23880140 |
2013 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, combination treatment of AxCATP53 and CDDP may be a new strategy for treating ovarian cancer with or without the TP53 gene.
|
10974636 |
2000 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
We have extended our LOH analysis of chromosome 3p to include 102 ovarian tumor specimens (29 and 73 samples were previously examined for LOH of chromosome 3p and 17 markers, respectively), using additional polymorphic markers, to assess the coordinate LOH of loci representing the three chromosome 3p minimal regions of deletions [von Hippel-Lindau syndrome (VHL), thyroid hormone receptor beta, and fragile histidine triad (FHIT)] and LOH of other important loci [tumor protein 53 (TP53), breast cancer 1 early onset (BRCA1), breast cancer 2 early onset, retinoblastoma 1, ornithine carbamoyltransferase, and androgen receptor] or somatic mutations in TP53.
|
12112314 |
2002 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that Ssd could sensitize OVCA to CDDP independent of the p53 status through multiple signaling pathways.
|
29245943 |
2017 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients.
|
17488735 |
2007 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, Notch1 mRNA high expression is significantly associated with worsen OS in TP53 wild-type ovarian cancer patients, while it is significantly associated with better OS in TP53 mutation-type ovarian cancer patients.
|
26662955 |
2016 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRCA1, as well as TP53, can undergo LOH prior to stromal invasion in BRCA1-associated ovarian cancer.
|
10880552 |
2000 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Detection of cellular heterogeneity by DNA ploidy, 17 chromosome, and p53 gene in primary carcinoma and metastasis in a case of ovarian cancer.
|
8852451 |
1996 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors.
|
1776830 |
1992 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
|
10078924 |
1999 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In one extreme case, we identified two independent TP53 mutations in ovary tumors and omentum/peritoneum metastases, respectively.
|
24221193 |
2014 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.
|
25437714 |
2014 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
|
15501075 |
2004 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to determine the frequency of MSI using a panel of 16 dinucleotide markers: TP53, D17S250, CACNLB1, D18S58, D19S49, DXS538, DXS454, D5S117, D5S107, D6S284, D6S305, D9S171, D9S15, D11S554, D11S29, and D13S272 in tissue from patients with OC or BOT and to correlate the presence of MSI at these markers with the clinical information, such as FIGO stage, histological type, age, and survival in OC.
|
18488714 |
2008 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, using pair-matched wild-type p53 CDDP-sensitive (OV2008) and -resistant (C13*) cells, and p53-compromised CDDP-resistant cells (A2780cp, OCC-1, OVCAR-3 and SKOV3), we have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cells in response to CDDP; (ii) PPM1D, but not phosphoinositide-3-kinase-related kinase Ataxia Telangiectasia and Rad3 related protein (ATR), is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53.
|
21927021 |
2012 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have investigated a series of ovarian tumours for evidence of mutations in the p53 tumour suppressor gene.
|
8422653 |
1993 |
|
ovarian neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of methods to detect p53 mutations in ovarian cancer.
|
11244334 |
2001 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.
|
10195884 |
1999 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The p53 expression in metastatic lesions may reflect an aggressive biologic behavior in ovarian cancer.
|
10053108 |
1999 |
|
ovarian neoplasm
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.
|
16969087 |
2006 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers.
|
30258081 |
2018 |
|
ovarian neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The results of our study indicate that presence of two aberrations in TP53 on 17p and LOH on 19q in early stage serous ovarian cancer is associated with recurrent disease.
|
22967087 |
2012 |